Shoreline picks up technology platform rights and access from Editas, which recently reduced staff. Hyloris out-licenses commercial rights to Maxigesic in nine EU markets to Salus.

With successful Phase III data, Merck will look to add biliary tract cancer to Keytruda’s label, but it will discontinue a Phase III study in prostate cancer after an interim analysis showed no survival benefit.

Many of the same factors that held down large M&A transactions in 2021 carried over to 2022, which saw eight buyouts valued at $2bn+, headlined by Amgen’s $27.8bn purchase of Horizon.

Following two workforce cuts in 2022, Finch said it will cut its staff by 95%, halting a Phase III study of lead recurrent C. diff candidate CP101 and seeking to maximize shareholder value.

The Japanese pharma agreed to pay $400m up front plus up to $730m in milestones for a colorectal cancer drug already on the market in China and nearing regulatory filings in the US, EU and Japan.

The BTK inhibitor demonstrated superiority to AbbVie/J&J’s Imbruvica for overall response in relapsed/refractory CLL, in addition to hitting a progression-free survival endpoint versus chemotherapy in the first-line.